Related Experiment Video
Updated: May 26, 2026

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
Bone metabolism in cholestatic children before and after living-related liver transplantation--a long-term
Edyta Kryskiewicz1, Joanna Pawlowska, Pawel Pludowski
1Department of Biochemistry and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland.
Insights
Successful living-related liver transplantation (LRLTx) in cholestatic children improves bone metabolism and bone mineral density in the short term. However, long-term follow-up shows moderately impaired bone status and metabolism, with bone markers predicting these changes.
Area of Science:
- Pediatric Hepatology
- Pediatric Endocrinology
- Orthopedics
Background:
- Children with end-stage liver disease, particularly cholestasis, frequently develop bone disorders.
- Risk factors include impaired liver function, altered vitamin D and calcium-phosphorus metabolism, malnutrition, and immunosuppressive therapy.
- Liver transplantation is a potential treatment, but its long-term effects on bone health require investigation.
Purpose of the Study:
- To evaluate the long-term impact of successful living-related liver transplantation (LRLTx) on skeletal status and bone metabolism in children with cholestatic liver disease.
Main Methods:
- A cohort of 18 cholestatic children undergoing LRLTx was studied.
- Bone metabolism markers (osteocalcin, P1NP, CTx, IGF-I, IGFBP-3, PTH, vitamin D metabolites) and bone mineral status (TBBMC, TBBMD via DXA) were measured before and up to 4.4 years post-transplantation.
- Data were compared to age-matched controls and analyzed for correlations.
Main Results:
- Pre-LRLTx, children exhibited decreased bone markers and bone mineral density compared to controls.
- Post-LRLTx, bone markers and bone mineral density normalized in the short term, correlating with IGF-I and PTH.
- Long-term (V4), P1NP and PTH levels deviated from reference ranges, coinciding with reduced bone mineral density Z-scores; P1NP and CTx showed predictive value for bone status changes.
Conclusions:
- LRLTx initially restores bone metabolism and improves bone mineral content and density in cholestatic children.
- Long-term monitoring reveals persistent, moderately impaired bone status and metabolic disturbances.
- Bone turnover markers like P1NP and CTx are valuable predictors of bone status evolution after LRLTx.
Abstract:
Bone disorders are common in children with end-stage liver diseases, especially those associated with cholestasis. Abnormal hepatocyte function, disordered vitamin D metabolism and calcium-phosphorous homeostasis, malnutrition, and immunosuppressive treatment are potential risk factors of bone tissue pathology before and after transplantation. The aim of the study was to analyze the long-term effect of successful living-related liver transplantation (LRLTx) on skeletal status and bone metabolism in cholestatic children. Eighteen cholestatic children (1.4±0.5yr old; 12 females [F]/6 males [M]) qualified for LRLTx were analyzed; 16 (5F/11M) of them participated in long-term observation (V4). Serum levels of osteocalcin (OC), procollagen type 1 N-terminal propeptide (P1NP), cross-linked telopeptide of type 1 collagen (CTx), insulin-like growth factor I (IGF-I), IGF-I binding protein 3 (IGFBP-3), parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), and 1,25-dihydroxyvitamin D (1,25(OH)(2)D) were assayed before (V0) and 6mo (V1), 12mo (V2), 18mo (V3), and 4.4yr (V4) after LRLTx. Total body bone mineral content (TBBMC) and total body bone mineral density (TBBMD) were measured by dual-energy X-ray absorptiometry (DXA) at the same pattern. Before LRLTx, the OC, P1NP, CTx, IGF-I, and IGFBP-3 levels as well as TBBMC and TBBMD were decreased compared with age-matched control group. The mean serum levels of 25(OH)D and 1,25(OH)(2)D were within reference ranges from V0 to V4. After LRLTx, the OC, P1NP, CTx, IGF-I, and IGFBP-3 as well as TBBMC and TBBMD reached the age-matched reference values. At V4, the level of P1NP decreased below and the PTH increased above the reference range that coincided with reduced Z-scores of both TBBMC (-1.11±1.24) and TBBMD (-1.00±1.19). P1NP and CTx, both measured at V3, correlated with IGF-I at V2 (R=0.86, p=0.014 and R=0.78, p=0.021, respectively) and PTH at V3 for P1NP and V1 for CTx (R=0.64, p=0.048 and R=0.54, p=0.038, respectively). The TBBMC changes between V0 and V4 correlated with IGF-I (R=0.68, p=0.015) and 1,25(OH)(2)D (R=0.54, p=0.025), both assayed at V1. The change of TBBMC Z-scores between V0 and V4 correlated with P1NP at V1 (R=0.69, p=0.002). The TBBMD changes between V0 and V4 correlated with CTx at V1 (R=0.54, p=0.027) and P1NP change between V0 and V1 (R=0.51, p=0.038). In short-term observation, successful LRLTx led to bone metabolism normalization triggered by probable anabolic action of IGF-I and PTH and manifested by TBBMC and TBBMD increases. In long-term horizon, moderately impaired DXA assessed bone status coincided with disturbances in bone metabolism. Bone metabolism markers, especially P1NP and CTx, appeared to be good predictors of changes in bone status evaluated by DXA.
Related Concept Videos
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism

